Jupiter Neurosciences Sold 11.47M Shares for $3.6M Under SEPA, Outstanding Shares Hit 56.5M

summarizeSummary

Jupiter Neurosciences sold 11.47 million shares to Yorkville under its SEPA for $3.6 million, bringing total outstanding shares to 56.5 million. The sales occurred between May 14 and July 24, 2026, at deeply discounted prices.

check_boxKey Events · Financing and Capital Events · JUNS

• 11.47M Shares Sold Under SEPA

  Between May 14 and July 24, 2026, the company issued 11,470,000 shares to Yorkville under the Standby Equity Purchase Agreement, raising $3.6 million in gross proceeds.

• Deeply Discounted Pricing

  Shares were sold at 97% of the lowest daily VWAP during each three-day pricing period, a structure that heavily dilutes existing shareholders at depressed prices.

• Outstanding Shares Surge to 56.5M

  Following the sales, total shares outstanding reached 56,520,143 as of July 28, 2026, representing roughly 20% dilution from the latest round alone.

• Going Concern and Delisting Risks Persist

  The company continues to operate under a going-concern warning and faces Nasdaq delisting; the SEPA remains a critical but dilutive funding source.

auto_awesomeAnalysis · JUNS · Life Sciences

Jupiter Neurosciences disclosed it sold 11.47 million shares to Yorkville under its SEPA between May 14 and July 24, 2026, raising $3.6 million. The per-share price was 97% of the lowest VWAP during each pricing period — a deeply dilutive structure for a stock trading at $0.1058. With 56.5 million shares now outstanding, the latest round alone represents roughly 20% dilution to prior holders. The company remains under a going-concern warning and faces Nasdaq delisting; this filing confirms it continues to rely on the SEPA for survival funding, further pressuring the share price.